Studies Validate Uniqueness of BVA-100 Blood Test for Heart Failure

Daxor Corporation has released new data from Duke Heart validating the benefits of the BVA-100 blood test in optimizing individualized therapy for heart failure patients. 
 
Studies from Duke Heart utilizing the company’s Daxor BVA-100 diagnostic in patients with an implantable pulmonary pressure monitor highlighted that the commonly used pressure metric does not correlate with actual blood volume. “The clinical implications are significant, as managing patients for cardiovascular congestion based on pressure measures alone might not be sufficient. Pressure measures provide complementary but different information. Pressure is not volume,” said Marat Fudim, M.D., principal study investigator.
 
“Heart failure management is centered around effective volume management, pressure measures are no substitute for direct 98% accurate measurement of blood volume with the Daxor BVA system. These two studies add to the considerable evidence that shows why BVA is the most accurate and effective diagnostic tool for volume measurement in heart failure with significant outcome and cost improvement for patient care when used to guide treatment,” Daxor Chief Scientific Officer Jonathan Feldschuh said.
 
Highlights from the two studies included:

• “Pressure-Volume Profiles in Heart Failure with Reduced Ejection Fraction and Heart Failure with Preserved Ejection Fraction”: This study compared the differences in pressure-volume profiles between two common heart failure phenotypes. Patients with reduced ejection fraction had overall higher pressures and blood volume than those with preserved ejection fraction, however there was lack of correlation between pressure and volume in both heart failure phenotypes. 
   
• “Correlation Between Pressure and Volume in Ambulatory Heart Failure: Sex-Specific Analysis”: Differences in cardiac structure and physiology exist between women and men with heart failure. Despite similar baseline characteristics, men had higher absolute total blood volume and greater total blood volume percent deviation compared to women with similar pressures. Overall, there was a discordance between pressure and volume measures in both men and women suggesting preferential response to diuretics to improve congestion in men. 

Daxor Corporation develops blood volume measurement technology focused on blood volume testing innovation. The company’s BVA-100 (Blood Volume Analyzer) is marketed as the only diagnostic blood test cleared by the U.S. Food and Drug Administration to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. More than 60,000 tests have been performed at U.S. hospitals, enhancing performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing multicenter trials in the areas of COVID-19 and heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor’s mission is to advance healthcare by enabling optimal fluid management with blood volume analysis.